Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria.
This longitudinal prospective study shows that antibodies to the N-terminal block 2 region of the Plasmodium falciparum merozoite surface protein 1 (MSP-1) are associated with protection against clinical malaria in an area of stable but seasonal malaria transmission of Ghana. Antibodies to the block 2 region of MSP-1 were measured in a cohort of 280 children before the beginning of the major malaria transmission season. The cohort was then actively monitored for malaria, clinically and parasitologically, over a period of 17 months. Evidence is presented for an association between antibody responses to block 2 and a significantly reduced risk of subsequent clinical malaria. Furthermore, statistical survival analysis provides new information on the duration of the effect over time. The results support a conclusion that the block 2 region of MSP-1 is a target of protective immunity against P. falciparum and, thus, a promising new candidate for the development of a malaria vaccine.
Item Type | Article |
---|---|
ISI | 224664300038 |
Explore Further
Read more research from the creator(s):
Find work associated with the faculties and division(s):
Find work associated with the research centre(s):
Find work from this publication:
Find other related resources:
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC522997 (OA Location)
- 10.1128/IAI.72.11.6492-6502.2004 (DOI)
- 15501780 (PubMed)